Back to top
more

Prothena (PRTA)

(Real Time Quote from BATS)

$22.03 USD

22.03
91,099

-0.07 (-0.32%)

Updated Jun 5, 2024 03:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PRTA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Prothena Corporation plc [PRTA]

Reports for Purchase

Showing records 241 - 260 ( 331 total )

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 241

12/11/2015

Industry Report

Pages: 6

Biotechnology/Biopharmaceuticals - ASH Recap 2015

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 242

12/10/2015

Daily Note

Pages: 6

ASH Roundup: Focus on AL Amyloidosis

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 243

11/24/2015

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 244

11/20/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 245

11/03/2015

Company Report

Pages: 8

3Q in Line Ahead of Busy 2016; Reiterate Outperform

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 246

10/16/2015

Daily Note

Pages: 5

Second Study for NEOD001 May Mean Acceleration; Reiterate OUTPERFORM and $81 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 247

10/16/2015

Daily Note

Pages: 5

Second Study for NEOD001 May Mean Acceleration; Reiterate OUTPERFORM and $81 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 248

10/02/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of October 5

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 249

08/05/2015

Company Report

Pages: 7

Prothena Advances Pipeline in 2Q15; Reiterate OUTPERFORM and $81 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 250

08/04/2015

Company Report

Pages: 7

NEOD001 Should Get Broad Use; Revising Estimates and Increasing PT to $81

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 251

06/17/2015

Daily Note

Pages: 5

Details on PRX002 Presented at Parkinson''s Conference; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 252

06/17/2015

Daily Note

Pages: 5

Details on PRX002 Presented at Parkinson''s Conference; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 253

06/09/2015

Daily Note

Pages: 5

Prothena Expands Clinical Portfolio with PRX003

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 254

06/02/2015

Company Report

Pages: 8

Responses Continue to Improve Over Time for NEOD001 in Amyloidosis; Raising Price Target to $53

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 255

05/22/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 25th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 256

05/14/2015

Industry Report

Pages: 9

ASCO 2015 Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 257

05/05/2015

Company Report

Pages: 7

1Q15 Earnings In-Line as Prothena Advances Three Clinical Programs

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 258

05/04/2015

Company Report

Pages: 5

Promising Parkinson''s Program Procures Partner

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 259

05/04/2015

Daily Note

Pages: 5

Promising Parkinson''s Program Procures Partner

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Prothena Corporation plc

Industry: Medical - Biomedical and Genetics

Record: 260

03/19/2015

Daily Note

Pages: 4

PRX002 on Target

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party